AU756094B2 - Antigenic peptides derived from telomerase - Google Patents

Antigenic peptides derived from telomerase Download PDF

Info

Publication number: AU756094B2
Authority: AU; Australia
Prior art keywords: peptide; seq; cancer; telomerase; cell response
Prior art date: 1998-07-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

AU45340/99A

Other languages

English (en)

Other versions

AU4534099A (en

Inventor

Jon Amund Eriksen

Gustav Gaudernack

Marianne Klemp Gjertsen

Mona Moller

Stein Saeboe-Larsen

Ingvil Saeterdal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gemvax AS

Original Assignee

Gemvax AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-08

Filing date

1999-06-30

Publication date

2003-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU756094(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-30 Application filed by Gemvax AS filed Critical Gemvax AS

2000-02-01 Publication of AU4534099A publication Critical patent/AU4534099A/en

2002-03-28 Assigned to GEMVAX AS reassignment GEMVAX AS Alteration of Name(s) of Applicant(s) under S113 Assignors: NORSK HYDRO ASA

2003-01-02 Application granted granted Critical

2003-01-02 Publication of AU756094B2 publication Critical patent/AU756094B2/en

2019-06-30 Anticipated expiration legal-status Critical

Status Expired legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 211
108010017842 Telomerase Proteins 0.000 title claims description 126
102000004196 processed proteins & peptides Human genes 0.000 title description 83
230000000890 antigenic effect Effects 0.000 title description 2
206010028980 Neoplasm Diseases 0.000 claims description 76
210000001744 T-lymphocyte Anatomy 0.000 claims description 67
108090000623 proteins and genes Proteins 0.000 claims description 45
201000011510 cancer Diseases 0.000 claims description 39
102000004169 proteins and genes Human genes 0.000 claims description 39
230000005867 T cell response Effects 0.000 claims description 35
238000000034 method Methods 0.000 claims description 35
150000001413 amino acids Chemical class 0.000 claims description 27
239000008194 pharmaceutical composition Substances 0.000 claims description 24
108700020796 Oncogene Proteins 0.000 claims description 23
210000004881 tumor cell Anatomy 0.000 claims description 22
102000039446 nucleic acids Human genes 0.000 claims description 21
108020004707 nucleic acids Proteins 0.000 claims description 21
150000007523 nucleic acids Chemical class 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 19
102000043276 Oncogene Human genes 0.000 claims description 16
238000011321 prophylaxis Methods 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 11
239000003085 diluting agent Substances 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims description 11
230000001939 inductive effect Effects 0.000 claims description 9
108010044720 telomerase reverse transcriptase (540-548) Proteins 0.000 claims description 9
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 6
201000001441 melanoma Diseases 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
201000009030 Carcinoma Diseases 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims description 4
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
206010006187 Breast cancer Diseases 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims description 2
206010008342 Cervix carcinoma Diseases 0.000 claims description 2
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
201000000582 Retinoblastoma Diseases 0.000 claims description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
210000003445 biliary tract Anatomy 0.000 claims description 2
201000010881 cervical cancer Diseases 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
210000004027 cell Anatomy 0.000 description 70
235000018102 proteins Nutrition 0.000 description 31
239000000203 mixture Substances 0.000 description 25
239000000427 antigen Substances 0.000 description 15
108091007433 antigens Proteins 0.000 description 15
102000036639 antigens Human genes 0.000 description 15
241000282414 Homo sapiens Species 0.000 description 14
108020004414 DNA Proteins 0.000 description 12
230000000694 effects Effects 0.000 description 12
108010074032 HLA-A2 Antigen Proteins 0.000 description 11
102000025850 HLA-A2 Antigen Human genes 0.000 description 11
125000003275 alpha amino acid group Chemical group 0.000 description 11
239000012636 effector Substances 0.000 description 10
108091035539 telomere Proteins 0.000 description 9
210000003411 telomere Anatomy 0.000 description 9
102000055501 telomere Human genes 0.000 description 9
230000028993 immune response Effects 0.000 description 8
230000035772 mutation Effects 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
230000007969 cellular immunity Effects 0.000 description 7
239000012634 fragment Substances 0.000 description 7
210000000612 antigen-presenting cell Anatomy 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
230000004044 response Effects 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
108700028369 Alleles Proteins 0.000 description 5
108010033276 Peptide Fragments Proteins 0.000 description 5
102000007079 Peptide Fragments Human genes 0.000 description 5
108700020978 Proto-Oncogene Proteins 0.000 description 5
102000052575 Proto-Oncogene Human genes 0.000 description 5
108700025695 Suppressor Genes Proteins 0.000 description 5
241000223892 Tetrahymena Species 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000009566 cancer vaccine Methods 0.000 description 5
229940022399 cancer vaccine Drugs 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
102100024553 Telomerase protein component 1 Human genes 0.000 description 4
102100032938 Telomerase reverse transcriptase Human genes 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
230000005945 translocation Effects 0.000 description 4
108010041986 DNA Vaccines Proteins 0.000 description 3
229940021995 DNA vaccine Drugs 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 3
101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 3
102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000030741 antigen processing and presentation Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
206010022000 influenza Diseases 0.000 description 3
238000011275 oncology therapy Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000000644 propagated effect Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
108010010995 MART-1 Antigen Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000011394 anticancer treatment Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000009758 senescence Effects 0.000 description 2
238000004904 shortening Methods 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
244000308180 Brassica oleracea var. italica Species 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
238000011238 DNA vaccination Methods 0.000 description 1
101710113436 GTPase KRas Proteins 0.000 description 1
102100039788 GTPase NRas Human genes 0.000 description 1
108010035452 HLA-A1 Antigen Proteins 0.000 description 1
108010086377 HLA-A3 Antigen Proteins 0.000 description 1
108010091938 HLA-B7 Antigen Proteins 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
108010025076 Holoenzymes Proteins 0.000 description 1
101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241001243761 Human hepatitis A virus Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
108010028921 Lipopeptides Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
101000762440 Pseudophryne guentheri Bombesin-like peptide L Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
239000012317 TBTU Substances 0.000 description 1
102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000032677 cell aging Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
-1 for example Proteins 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000003019 stabilising effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003277 telomerase inhibitor Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
239000013598 vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU45340/99A 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase Expired AU756094B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
NO19983141A NO313834B1 (no)	1998-07-08	1998-07-08	Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt
NO19983141		1998-07-08
PCT/NO1999/000220 WO2000002581A1 (en)	1998-07-08	1999-06-30	Antigenic peptides derived from telomerase

Publications (2)

Publication Number	Publication Date
AU4534099A AU4534099A (en)	2000-02-01
AU756094B2 true AU756094B2 (en)	2003-01-02

Family

ID=19902234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU45340/99A Expired AU756094B2 (en)	1998-07-08	1999-06-30	Antigenic peptides derived from telomerase

Country Status (20)

Country	Link
US (2)	US7030211B1 (cs)
EP (4)	EP2316476B1 (cs)
JP (2)	JP4618657B2 (cs)
CN (1)	CN100376290C (cs)
AR (2)	AR020601A1 (cs)
AT (2)	ATE247484T1 (cs)
AU (1)	AU756094B2 (cs)
CA (2)	CA2336743C (cs)
CY (1)	CY1109978T1 (cs)
CZ (1)	CZ303215B6 (cs)
DE (2)	DE69910580T3 (cs)
DK (2)	DK1093381T4 (cs)
ES (2)	ES2200526T5 (cs)
HK (1)	HK1039068B (cs)
HU (1)	HU230007B1 (cs)
NO (1)	NO313834B1 (cs)
PL (1)	PL203815B1 (cs)
PT (2)	PT1362597E (cs)
TW (1)	TWI261617B (cs)
WO (1)	WO2000002581A1 (cs)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0954585B1 (en)	1996-10-01	2009-11-25	Geron Corporation	Human telomerase reverse transcriptase promoter
US6475789B1 (en)	1996-10-01	2002-11-05	University Technology Corporation	Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en)	1996-10-01	2009-09-08	Geron Corporation	Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7622549B2 (en)	1997-04-18	2009-11-24	Geron Corporation	Human telomerase reverse transcriptase polypeptides
US7413864B2 (en)	1997-04-18	2008-08-19	Geron Corporation	Treating cancer using a telomerase vaccine
EP1068296B1 (en)	1998-03-31	2011-08-10	Geron Corporation	Compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en)	1998-03-31	2008-07-22	Geron Corporation	Method for identifying and killing cancer cells
CA2344972A1 (en)	1998-10-29	2000-05-11	Dana-Farber Cancer Institute, Inc.	Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
WO2000061766A2 (en) *	1999-04-09	2000-10-19	Biomira, Inc.	Telomerase-specific cancer vaccine
EP1257284A4 (en) *	2000-02-15	2005-12-21	Univ California	UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
AU2001241533A1 (en)	2000-02-15	2001-08-27	The Regents Of The University Of California	A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr)	2000-07-21	2007-05-11	Inst Nat Sante Rech Med	Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) *	2000-12-22	2001-02-07	Norsk Hydro As	Polypeptides
GB0105238D0 (en) *	2001-03-02	2001-04-18	Norsk Hydro As	Vaccines
GB0112342D0 (en) *	2001-05-21	2001-07-11	Norsk Hydro As	Polypeptides
EP1601684B1 (en) *	2003-03-05	2014-10-15	Dendreon Corporation	Alternative reading frame polypeptides for treatment
EP1748067A1 (en) *	2005-07-29	2007-01-31	Institut Pasteur	Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US10767167B2 (en)	2005-07-29	2020-09-08	Institut Pasteur	Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
JP2009523817A (ja) *	2006-01-19	2009-06-25	ザリージェンツオブザユニバーシティオブカリフォルニア	ヒトテロメラーゼ逆転写酵素ペプチド
US9732131B2 (en)	2006-02-27	2017-08-15	Calviri, Inc.	Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) *	2006-07-12	2008-01-24	Vaxon Biotech	Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (en) *	2006-08-10	2008-02-13	International Investment and Patents SA	Plasmids with immunological action
JP5207354B2 (ja) *	2008-03-12	2013-06-12	独立行政法人産業技術総合研究所	転写抑制ペプチド及びその遺伝子
PL2310044T3 (pl) *	2008-06-16	2017-04-28	Mediolanum Farmaceutici S.P.A.	Immunoterapia przeciwnowotworowa
EP2337795A2 (en) *	2008-10-01	2011-06-29	Dako Denmark A/S	Mhc multimers in cancer vaccines and immune monitoring
GB0821616D0 (en)	2008-11-26	2008-12-31	Lytix Biopharma As	Compounds
BR112012011731A2 (pt)	2009-11-10	2020-08-25	Allegro Pharmaceuticals, Inc.	composições e métodos para inibir a adesão celular ou direcionamento dos agentes de diagnóstico ou terapêuticos para os sítios de ligação rgd
US11673914B2 (en)	2009-11-10	2023-06-13	Allegro Pharmaceuticals, LLC	Peptide therapies for reduction of macular thickening
EP2536830B1 (en)	2010-02-16	2019-07-17	Ultimovacs AS	Polypeptides
FR2960542B1 (fr) *	2010-05-27	2012-08-17	Esther Suzy Arlette Fellous	Peptide en tant que medicament, en particulier pour le traitement du cancer
KR102165421B1 (ko) *	2011-05-09	2020-10-14	알레그로 파마슈티칼스, 인코포레이티드.	인테그린 수용체 길항물질 및 이의 사용 방법
EP3333180B1 (en) *	2012-05-11	2019-08-21	KAEL-GemVax Co.,Ltd	Anti-inflammatory peptides and composition comprising the same
EP2875826B1 (en) *	2012-05-11	2017-08-23	KAEL-GemVax Co.,Ltd	Composition for preventing or treating sepsis
CN115927242A (zh) *	2012-05-11	2023-04-07	珍白斯凯尔有限公司	具有抗炎活性的肽及其在制备抗炎组合物中的应用
JP6272853B2 (ja) *	2012-07-11	2018-01-31	ジェムバックスアンドカエルカンパニー，リミティド	細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20150125438A1 (en) *	2012-07-20	2015-05-07	Sang Jae Kim	Anti-Inflammatory Peptides and Composition Comprising the Same
WO2014046478A1 (ko) *	2012-09-19	2014-03-27	주식회사 카엘젬백스	세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN110064056B (zh) *	2012-09-19	2022-10-28	珍白斯凯尔有限公司	细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
TWI616530B (zh) *	2012-09-19	2018-03-01	傑姆維克斯＆凱爾有限公司	穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
WO2014046490A1 (ko) *	2012-09-19	2014-03-27	주식회사 카엘젬백스	세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
KR102038487B1 (ko)	2012-09-19	2019-10-30	주식회사 젬백스앤카엘	텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
KR102166542B1 (ko)	2012-09-28	2020-10-16	주식회사 젬백스앤카엘	줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) *	2012-10-22	2014-04-09	南京工业大学	一种制备端粒酶多肽疫苗的方法
KR102106756B1 (ko)	2012-12-13	2020-05-06	주식회사 젬백스앤카엘	자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko)	2012-12-13	2020-03-25	주식회사 젬백스앤카엘	피부 노화 개선용 조성물
KR102258864B1 (ko) *	2013-04-19	2021-06-01	주식회사 젬백스앤카엘	허혈성 손상 치료 및 예방용 조성물
TWI634210B (zh) *	2013-05-03	2018-09-01	傑姆維克斯＆凱爾有限公司	抑制熱休克蛋白質表現之胜肽及包含其之組成物
CA2912557A1 (en)	2013-06-07	2014-12-11	Gemvax & Kael Co., Ltd.	Biological markers useful in cancer immunotherapy
TWI539960B (zh) *	2013-06-21	2016-07-01	凱爾傑姆維克斯有限公司	激素分泌調節劑、包括其的組成物以及其用途
EP3020724A4 (en) *	2013-07-12	2017-01-18	Gemvax & Kael Co., Ltd.	Cell-penetrating peptide and conjugate comprising same
KR102204476B1 (ko) *	2013-08-14	2021-01-19	주식회사 젬백스앤카엘	다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) *	2013-09-06	2013-10-23	Immune Targeting Systems Its Ltd	Oncology vaccine
ES2773296T3 (es) *	2013-10-23	2020-07-10	Gemvax & Kael Co Ltd	Composición para tratar y prevenir la hiperplasia prostática benigna
KR102494803B1 (ko) *	2013-11-22	2023-02-06	주식회사 젬백스앤카엘	혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR102106757B1 (ko) *	2013-11-29	2020-05-06	주식회사 젬백스앤카엘	난소 동결 보존용 펩티드 및 이를 포함하는 조성물
KR20160097244A (ko) *	2013-12-10	2016-08-17	주식회사 젬백스앤카엘	항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
CN105939723B (zh) *	2013-12-17	2020-02-28	珍白斯凯尔有限公司	前列腺癌治疗用组合物
KR102166549B1 (ko)	2014-01-10	2020-10-16	주식회사 젬백스앤카엘	혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) *	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
KR102373603B1 (ko) *	2014-04-11	2022-03-14	주식회사 젬백스앤카엘	섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015170790A1 (ko) *	2014-05-09	2015-11-12	주식회사 카엘젬백스	허혈성 손상 치료 및 예방용 조성물
EP3138399B1 (en)	2014-04-30	2023-09-06	Gemvax & Kael Co., Ltd.	Composition for organ, tissue, or cell transplantation, kit, and transplantation method
CN105601713B (zh) *	2014-05-29	2019-10-22	张健	一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) *	2014-06-02	2020-10-16	주식회사 젬백스앤카엘	켈로이드 억제용 조성물 및 그 억제 방법
KR102413243B1 (ko)	2014-12-23	2022-06-27	주식회사 젬백스앤카엘	안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102397510B1 (ko) *	2014-12-23	2022-05-13	주식회사 젬백스앤카엘	난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR102636129B1 (ko)	2015-02-27	2024-02-14	주식회사 젬백스앤카엘	청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
EP3305802B1 (en)	2015-05-26	2021-05-12	Gemvax & Kael Co., Ltd.	Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same
US11015179B2 (en)	2015-07-02	2021-05-25	Gemvax & Kael Co., Ltd.	Peptide having anti-viral effect and composition containing same
KR20170054310A (ko) *	2015-11-09	2017-05-17	주식회사 젬백스앤카엘	텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
KR20180123512A (ko)	2016-04-07	2018-11-16	주식회사 젬백스앤카엘	텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN112210010B (zh)	2017-01-06	2023-12-05	优特力克斯有限公司	抗-人4-1bb抗体及其应用
EP3576764A4 (en)	2017-02-03	2020-12-16	The Medical College of Wisconsin, Inc.	KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE
EP3630130B1 (en)	2017-06-02	2022-08-31	Arizona Board of Regents on behalf of Arizona State University	A method to create personalized cancer vaccines
US12025615B2 (en)	2017-09-15	2024-07-02	Arizona Board Of Regents On Behalf Of Arizona State University	Methods of classifying response to immunotherapy for cancer
WO2020002650A1 (en)	2018-06-29	2020-01-02	Targovax Asa	A formulation
WO2021067550A1 (en)	2019-10-02	2021-04-08	Arizona Board Of Regents On Behalf Of Arizona State University	Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2021212015A2 (en) *	2020-04-17	2021-10-21	Lineage Cell Therapeutics, Inc.	Mhc restricted immunogenic telomerase reverse transcriptase -specific peptides, their complex conjugates, and methods of using the same
WO2024253422A1 (ko) *	2023-06-08	2024-12-12	주식회사 젬백스앤카엘	Gv1001를 포함하는 치주질환 및 치주질환에 의한 장애의 예방 또는 치료용 조성물
WO2025123056A1 (en) *	2023-12-07	2025-06-12	Endevica Bio, Inc.	Non-naturally occurring melanocortin analogs and associated methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997035619A1 (en) *	1996-03-28	1997-10-02	Genitrix, L.L.C.	Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
WO1998001542A1 (en) *	1996-07-08	1998-01-15	The Regents Of The University Of California	Human telomerase
WO1998014593A2 (en) *	1996-10-01	1998-04-09	Geron Corporation	Human telomerase catalytic subunit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9103974D0 (en)	1991-02-26	1991-04-10	Norsk Hydro As	Therapeutically useful peptides or peptide fragments
EP0765386B1 (en)	1994-06-14	2014-12-10	The Board Of Trustees Of The Leland Stanford Junior University	Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5968506A (en)	1995-08-04	1999-10-19	Geron Corporation	Purified telomerase
ES2184990T3 (es) *	1996-02-12	2003-04-16	Ml Lab Plc	Nuevos metodos de vacunacion y vacunas para los mismos que comprenden un acido nucleico que codifica un primer epitope y un peptido que contiene un segundo epitope.
ES2241051T3 (es) *	1996-07-08	2005-10-16	Vivoxid Oy	Material biodegradable de alta resistencia al impacto.
US7390891B1 (en) *	1996-11-15	2008-06-24	Amgen Inc.	Polynucleotides encoding a telomerase component TP2
EP1068296B1 (en)	1998-03-31	2011-08-10	Geron Corporation	Compositions for eliciting an immune response to a telomerase antigen
US6337200B1 (en)	1998-03-31	2002-01-08	Geron Corporation	Human telomerase catalytic subunit variants

1990
- 1990-06-30 US US09/743,281 patent/US7030211B1/en not_active Expired - Lifetime
1998
- 1998-07-08 NO NO19983141A patent/NO313834B1/no not_active IP Right Cessation
1999
- 1999-06-30 EP EP10183808.4A patent/EP2316476B1/en not_active Expired - Lifetime
- 1999-06-30 ES ES99928238T patent/ES2200526T5/es not_active Expired - Lifetime
- 1999-06-30 PT PT03075681T patent/PT1362597E/pt unknown
- 1999-06-30 JP JP2000558840A patent/JP4618657B2/ja not_active Expired - Lifetime
- 1999-06-30 HU HU0104889A patent/HU230007B1/hu unknown
- 1999-06-30 DK DK99928238T patent/DK1093381T4/da active
- 1999-06-30 CA CA 2336743 patent/CA2336743C/en not_active Expired - Lifetime
- 1999-06-30 AT AT99928238T patent/ATE247484T1/de active
- 1999-06-30 AT AT03075681T patent/ATE458494T1/de active
- 1999-06-30 CN CNB998099546A patent/CN100376290C/zh not_active Expired - Lifetime
- 1999-06-30 DK DK03075681T patent/DK1362597T3/da active
- 1999-06-30 ES ES03075681.1T patent/ES2341170T5/es not_active Expired - Lifetime
- 1999-06-30 EP EP99928238A patent/EP1093381B2/en not_active Expired - Lifetime
- 1999-06-30 DE DE1999610580 patent/DE69910580T3/de not_active Expired - Lifetime
- 1999-06-30 WO PCT/NO1999/000220 patent/WO2000002581A1/en not_active Ceased
- 1999-06-30 AU AU45340/99A patent/AU756094B2/en not_active Expired
- 1999-06-30 EP EP10154215.7A patent/EP2258383B1/en not_active Expired - Lifetime
- 1999-06-30 CZ CZ20010037A patent/CZ303215B6/cs not_active IP Right Cessation
- 1999-06-30 EP EP20030075681 patent/EP1362597B2/en not_active Expired - Lifetime
- 1999-06-30 PL PL345541A patent/PL203815B1/pl unknown
- 1999-06-30 DE DE69942072T patent/DE69942072D1/de not_active Expired - Lifetime
- 1999-06-30 PT PT99928238T patent/PT1093381E/pt unknown
- 1999-06-30 CA CA 2748996 patent/CA2748996A1/en not_active Abandoned
- 1999-06-30 HK HK02100577.9A patent/HK1039068B/zh not_active IP Right Cessation
- 1999-07-12 AR ARP990103374 patent/AR020601A1/es active IP Right Grant
- 1999-09-03 TW TW88115173A patent/TWI261617B/zh not_active IP Right Cessation
2006
- 2006-01-17 US US11/332,378 patent/US7794723B2/en not_active Expired - Fee Related
2010
- 2010-04-23 CY CY101100364T patent/CY1109978T1/el unknown
- 2010-07-15 AR ARP100102596 patent/AR077576A2/es unknown
- 2010-08-06 JP JP2010177870A patent/JP5491315B2/ja not_active Expired - Lifetime

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997035619A1 (en) *	1996-03-28	1997-10-02	Genitrix, L.L.C.	Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
WO1998001542A1 (en) *	1996-07-08	1998-01-15	The Regents Of The University Of California	Human telomerase
WO1998014593A2 (en) *	1996-10-01	1998-04-09	Geron Corporation	Human telomerase catalytic subunit

Also Published As

Publication number	Publication date
NO983141L (no)	2000-01-10
EP1362597A1 (en)	2003-11-19
CY1109978T1 (el)	2014-09-10
EP2258383A3 (en)	2011-05-11
ES2341170T5 (es)	2014-09-09
AR020601A1 (es)	2002-05-22
CN1313773A (zh)	2001-09-19
JP4618657B2 (ja)	2011-01-26
HUP0104889A2 (hu)	2002-04-29
CZ303215B6 (cs)	2012-05-30
EP1362597B2 (en)	2014-06-25
NO313834B1 (no)	2002-12-09
EP2316476A2 (en)	2011-05-04
DE69910580T3 (de)	2009-11-26
EP1093381A1 (en)	2001-04-25
JP5491315B2 (ja)	2014-05-14
EP1362597B1 (en)	2010-02-24
US20060106196A1 (en)	2006-05-18
JP2002520293A (ja)	2002-07-09
CZ200137A3 (en)	2001-06-13
AR077576A2 (es)	2011-09-07
ATE247484T1 (de)	2003-09-15
DE69942072D1 (de)	2010-04-08
US7794723B2 (en)	2010-09-14
US7030211B1 (en)	2006-04-18
EP2258383A2 (en)	2010-12-08
DE69910580D1 (de)	2003-09-25
CA2336743C (en)	2011-10-11
ATE458494T1 (de)	2010-03-15
HK1039068B (zh)	2009-02-06
CA2336743A1 (en)	2000-01-20
HUP0104889A3 (en)	2004-04-28
TWI261617B (en)	2006-09-11
HU230007B1 (en)	2015-04-28
EP1093381B1 (en)	2003-08-20
HK1039068A1 (zh)	2002-04-12
CN100376290C (zh)	2008-03-26
PL345541A1 (en)	2001-12-17
EP1093381B2 (en)	2009-07-22
ES2200526T5 (es)	2009-12-11
EP2316476A3 (en)	2011-09-14
DK1093381T3 (da)	2003-09-08
ES2341170T3 (es)	2010-06-16
AU4534099A (en)	2000-02-01
PT1093381E (pt)	2004-01-30
JP2010252810A (ja)	2010-11-11
PL203815B1 (pl)	2009-11-30
PT1362597E (pt)	2010-04-14
CA2748996A1 (en)	2000-01-20
EP2258383B1 (en)	2016-03-09
DK1362597T3 (da)	2010-06-14
EP2316476B1 (en)	2015-11-25
WO2000002581A1 (en)	2000-01-20
DK1093381T4 (da)	2009-09-21
ES2200526T3 (es)	2004-03-01
DE69910580T2 (de)	2004-06-24

Publication	Publication Date	Title
AU756094B2 (en)	2003-01-02	Antigenic peptides derived from telomerase
US8193326B2 (en)	2012-06-05	Nucleic acids encoding novel TERT polypeptides
AU2002216477A1 (en)	2003-01-23	Polypeptides
HK1155656A (en)	2012-05-25	Antigenic peptides derived from telomerase
HK1145642A (en)	2011-04-29	Antigenic peptides derived from telomerase
HK1156977A (en)	2012-06-22	Polypeptides capable of eliciting an immune reaction against cancer

Legal Events

Date	Code	Title	Description
2002-03-28	PC1	Assignment before grant (sect. 113)	Owner name: GEMVAX AS Free format text: THE FORMER OWNER WAS: NORSK HYDRO ASA
2003-05-01	FGA	Letters patent sealed or granted (standard patent)
2019-07-18	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Date

Code

Title

Description

2002-03-28

PC1

Assignment before grant (sect. 113)

Owner name: GEMVAX AS

Free format text: THE FORMER OWNER WAS: NORSK HYDRO ASA

2003-05-01

FGA

Letters patent sealed or granted (standard patent)

2019-07-18

MK14

Patent ceased section 143(a) (annual fees not paid) or expired